Anti-Platelets in Chronic Obstructive Pulmonary Disease

第2相完了 NCT05567562

対象疾患	COPD, Emphysema, Emphysema or COPD
相	第2相
スポンサー	Brigham and Women's Hospital
ステータス	完了
参加者数	15 名
介入（薬剤）	dual anti-platelet therapy
開始日	2024年3月27日
完了日	2025年2月28日
結果公開日	2026年5月14日

概要

This is a 6 week crossover study in current and former smokers with and without COPD to evaluate whether 2 weeks of dual antiplatelet therapy (aspirin 81mg and clopidogrel 75mg) improves pulmonary perfusion (i.e. blood flow in the lungs measured on a contrast CT scan) compared to placebo.

Pulmonary Microvascular Blood Volume, CV

After 2 weeks of therapy · CV

On Dual Anti-platelet Therapy	0.89 ± 0.079 CV
On Placebo	0.88 ± 0.072 CV
On Dual Anti-platelet Therapy, COPD	0.92 ± 0.064 CV
On Placebo, COPD	0.91 ± 0.052 CV
On Dual Anti-platelet Therapy, Controls	0.81 ± 0.051 CV
On Placebo, Controls	0.80 ± 0.042 CV

p-value	0.84

BENITIONS で見る ClinicalTrials.gov の原文を見る

同じ疾患の他の治験

Feasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and — University of Tennessee Graduate School of Medicine
Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate Versus Foster — Chiesi Farmaceutici S.p.A.
Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®T — Chiesi Farmaceutici S.p.A.
Tiotropium/Salmeterol Inhalation Powder in COPD — Boehringer Ingelheim
Risk Factors, Costs, and Impacts of ED Boarding — University of Maryland, Baltimore
Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructiv — United Therapeutics

すべての治験

このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。

English 한국어 日本語中文 Русский